![Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib? - ScienceDirect Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib? - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497121045201-gr1.jpg)
Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib? - ScienceDirect
![Frontiers | The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients Frontiers | The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients](https://www.frontiersin.org/files/Articles/704773/fimmu-12-704773-HTML/image_m/fimmu-12-704773-t001.jpg)
Frontiers | The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
![Diagnostics | Free Full-Text | Head-to-Head Comparison of 5 Anti-SARS-CoV-2 Assays Performance in One Hundred COVID-19 Vaccinees, over an 8-Month Course Diagnostics | Free Full-Text | Head-to-Head Comparison of 5 Anti-SARS-CoV-2 Assays Performance in One Hundred COVID-19 Vaccinees, over an 8-Month Course](https://pub.mdpi-res.com/diagnostics/diagnostics-12-01426/article_deploy/html/images/diagnostics-12-01426-g001.png?1654762707)
Diagnostics | Free Full-Text | Head-to-Head Comparison of 5 Anti-SARS-CoV-2 Assays Performance in One Hundred COVID-19 Vaccinees, over an 8-Month Course
![Vaccines | Free Full-Text | Durability of Immune Response after Application of a Third Dose of SARS-CoV-2 Vaccination in Liver Transplant Recipients Vaccines | Free Full-Text | Durability of Immune Response after Application of a Third Dose of SARS-CoV-2 Vaccination in Liver Transplant Recipients](https://www.mdpi.com/vaccines/vaccines-11-00572/article_deploy/html/images/vaccines-11-00572-g001.png)
Vaccines | Free Full-Text | Durability of Immune Response after Application of a Third Dose of SARS-CoV-2 Vaccination in Liver Transplant Recipients
![Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination | npj Vaccines Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination | npj Vaccines](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41541-023-00626-w/MediaObjects/41541_2023_626_Fig1_HTML.png)
Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination | npj Vaccines
![Evaluation of the analytical performance of three chemiluminescence serological assays for detecting anti-SARS-CoV-2 antibodies | Clinical and Experimental Medicine Evaluation of the analytical performance of three chemiluminescence serological assays for detecting anti-SARS-CoV-2 antibodies | Clinical and Experimental Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10238-022-00918-w/MediaObjects/10238_2022_918_Fig2_HTML.png)
Evaluation of the analytical performance of three chemiluminescence serological assays for detecting anti-SARS-CoV-2 antibodies | Clinical and Experimental Medicine
![Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection - eBioMedicine Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection - eBioMedicine](https://www.thelancet.com/cms/attachment/2df55111-b384-4465-8788-e74623eb2ac2/gr1.jpg)